Your browser doesn't support javascript.
loading
A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry.
Middha, Pooja; Wang, Xiaoliang; Behrens, Sabine; Bolla, Manjeet K; Wang, Qin; Dennis, Joe; Michailidou, Kyriaki; Ahearn, Thomas U; Andrulis, Irene L; Anton-Culver, Hoda; Arndt, Volker; Aronson, Kristan J; Auer, Paul L; Augustinsson, Annelie; Baert, Thaïs; Freeman, Laura E Beane; Becher, Heiko; Beckmann, Matthias W; Benitez, Javier; Bojesen, Stig E; Brauch, Hiltrud; Brenner, Hermann; Brooks-Wilson, Angela; Campa, Daniele; Canzian, Federico; Carracedo, Angel; Castelao, Jose E; Chanock, Stephen J; Chenevix-Trench, Georgia; Cordina-Duverger, Emilie; Couch, Fergus J; Cox, Angela; Cross, Simon S; Czene, Kamila; Dossus, Laure; Dugué, Pierre-Antoine; Eliassen, A Heather; Eriksson, Mikael; Evans, D Gareth; Fasching, Peter A; Figueroa, Jonine D; Fletcher, Olivia; Flyger, Henrik; Gabrielson, Marike; Gago-Dominguez, Manuela; Giles, Graham G; González-Neira, Anna; Grassmann, Felix; Grundy, Anne; Guénel, Pascal.
Affiliation
  • Middha P; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. pooja.middha@ucsf.edu.
  • Wang X; Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA.
  • Behrens S; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Bolla MK; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Wang Q; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
  • Dennis J; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
  • Michailidou K; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
  • Ahearn TU; Department of Public Health and Primary Care, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
  • Andrulis IL; Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
  • Anton-Culver H; Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Arndt V; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
  • Aronson KJ; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Auer PL; Department of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
  • Augustinsson A; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Baert T; Department of Public Health Sciences, and Cancer Research Institute, Queen's University, Kingston, ON, Canada.
  • Freeman LEB; Division of Biostatistics, Institute for Health and Equity, and Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Becher H; Oncology, Clinical Sciences in Lund, Lund University, Lund, Sweden.
  • Beckmann MW; Department of Oncology, Leuven Multidisciplinary Breast Center, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
  • Benitez J; Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Bojesen SE; Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Brauch H; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Brenner H; Human Genetics Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Brooks-Wilson A; Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
  • Campa D; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Canzian F; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Carracedo A; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Castelao JE; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Chanock SJ; iFIT-Cluster of Excellence, University of Tübingen, Tübingen, Germany.
  • Chenevix-Trench G; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany.
  • Cordina-Duverger E; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Couch FJ; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Cox A; Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada.
  • Cross SS; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Czene K; Department of Biology, University of Pisa, Pisa, Italy.
  • Dossus L; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Dugué PA; Genomic Medicine Group, International Cancer Genetics and Epidemiology Group, Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
  • Eliassen AH; Grupo de Medicina Xenómica, Centro de Investigación en Red de Enfermedades Raras (CIBERER) y Centro Nacional de Genotipado (CEGEN-PRB2), Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
  • Eriksson M; Oncology and Genetics Unit, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.
  • Evans DG; Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Fasching PA; Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
  • Fletcher O; Team 'Exposome and Heredity', CESP, Gustave Roussy, INSERM, University Paris-Saclay, UVSQ, Villejuif, France.
  • Flyger H; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Gabrielson M; Department of Oncology and Metabolism, Sheffield Institute for Nucleic Acids (SInFoNiA), University of Sheffield, Sheffield, UK.
  • Gago-Dominguez M; Academic Unit of Pathology, Department of Neuroscience, University of Sheffield, Sheffield, UK.
  • Giles GG; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • González-Neira A; Nutrition and Metabolism Section, International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Grassmann F; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.
  • Grundy A; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
  • Guénel P; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Breast Cancer Res ; 25(1): 93, 2023 08 09.
Article in En | MEDLINE | ID: mdl-37559094
ABSTRACT

BACKGROUND:

Genome-wide studies of gene-environment interactions (G×E) may identify variants associated with disease risk in conjunction with lifestyle/environmental exposures. We conducted a genome-wide G×E analysis of ~ 7.6 million common variants and seven lifestyle/environmental risk factors for breast cancer risk overall and for estrogen receptor positive (ER +) breast cancer.

METHODS:

Analyses were conducted using 72,285 breast cancer cases and 80,354 controls of European ancestry from the Breast Cancer Association Consortium. Gene-environment interactions were evaluated using standard unconditional logistic regression models and likelihood ratio tests for breast cancer risk overall and for ER + breast cancer. Bayesian False Discovery Probability was employed to assess the noteworthiness of each SNP-risk factor pairs.

RESULTS:

Assuming a 1 × 10-5 prior probability of a true association for each SNP-risk factor pairs and a Bayesian False Discovery Probability < 15%, we identified two independent SNP-risk factor pairs rs80018847(9p13)-LINGO2 and adult height in association with overall breast cancer risk (ORint = 0.94, 95% CI 0.92-0.96), and rs4770552(13q12)-SPATA13 and age at menarche for ER + breast cancer risk (ORint = 0.91, 95% CI 0.88-0.94).

CONCLUSIONS:

Overall, the contribution of G×E interactions to the heritability of breast cancer is very small. At the population level, multiplicative G×E interactions do not make an important contribution to risk prediction in breast cancer.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Gene-Environment Interaction Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans Language: En Journal: Breast Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Gene-Environment Interaction Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans Language: En Journal: Breast Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: Alemania